
|Articles|August 18, 2016
EndoPredict vs Oncotype DX for Predicting Breast Cancer Recurrence
Author(s)Bobby Lazzara, MD
In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a recent study that compared EndoPredict and Oncotype DX, which both predict the likelihood of a breast cancer recurrence.
Advertisement
In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a recent study that compared EndoPredict and Oncotype DX, which both predict the likelihood of a breast cancer recurrence.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Subcutaneous Daratumumab Combination in NDMM
2
Developers Resubmit NDA for Rivoceranib/Camrelizumab in Unresectable HCC
3
Trispecific Antibody Earns FDA Fast Track Designation in Multiple Myeloma
4
FDA Grants BTD to Bezuclastinib Combo in Gastrointestinal Stromal Tumors
5



































